Abstract 767P
Background
Cisplatin-based concurrent chemoradiation therapy (CCRT) has been increasingly used for local advanced cervical cancer (LACC). However, recurrence is common after cisplatin-based CCRT. Several treatment strategies have been explored to further improve the outcome. We aimed to evaluate the safety and efficacy of anti-PD-1 (Toripalimab, a humanized immunoglobulin G monoclonal antibody against programmed death 1) combined with cisplatin-based concurrent IMRT for locally advanced cervical cancer.
Methods
This is an open-label, nonrandomized, prospective phase Ⅰ/II study in a single arm. Patients with untreated LACC (2018 FIGO stage IB3, IIA –IVA) were enrolled. All patients were treated with CCRT for 56 days including cisplatin (40 mg/m2, Q1W) combined with image-guidance volume modulated Arc therapy (IG-VMAT) to pelvis (50.4Gy in 28 fractions, pelvic and paraortic nodes with simultaneous nodal boost to 59.4 Gy, 28 fractions), and followed by HDR intracavitary (30-36 Gy in 5-6 fractions) brachytherapy. Toripalimab was administered intravenously at 240 mg every 2 week for 4 cycles. The primary endpoint was incidence and severity of acute adverse events up to 3 months of completing treatment. The secondary endpoints were ORR and PFS.
Results
From Sep 2020 to Sep 2022, a total of 30 patients were enrolled. Median age was 58 years [range: 23–71]. The median follow-up duration was 8.5 months [range: 3.2–27.3]. 29 patients (29/30, 96.7%) completed the treatment, 1 patient (1/30, 3.3%) terminated the treatment because of hemophagic syndrome, who with a history of liver fluke disease. ORR was 100.0% (30/30) at 3 months after treatment. Treatment-related grade 3 or 4 adverse events occurred in 80% (24/30) of patients, primarily leukopenia (63.3%), lymphopenia (36.7%), anemia (26.7%), neutropenia (16.7%). The grade 1-2 potentially immune-related adverse events were chromatosis 5 (16.7%), rash 2 (6.7%), pruritus 2 (6.7%), hypothyroidism 2 (6.7%), adrenal insufficiency 2 (6.7%), No treatment-related deaths occurred.
Conclusions
Toripalimab combined with cisplatin-based concurrent IMRT was tolerable and showed promising antitumor activity in patients with LACC, while immunotherapy-related toxicities should be carefully managed.
Clinical trial identification
NCT04368273.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Shanghai Junshi Biomedicine Technology Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
800P - Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Presenter: Sarah Howlett
Session: Poster session 11
802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Presenter: Frederik Marmé
Session: Poster session 11
803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Presenter: Shin Nishio
Session: Poster session 11
805P - Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Presenter: Christoph Grimm
Session: Poster session 11
806P - Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Presenter: Ainhoa Madariaga Urrutia
Session: Poster session 11
807P - Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Presenter: Shujuan Liu
Session: Poster session 11
808P - Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for monitoring treatment response and for detecting relapse in locally advanced cervical cancer
Presenter: Lars Sivars
Session: Poster session 11
809P - Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship
Presenter: jiangrong wang
Session: Poster session 11
810P - The influence of preoperative conization (pc) to patient’s (pts) outcome and tumor biology of cervical cancer (CC)
Presenter: Dimitra Trantaki
Session: Poster session 11
811P - Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Presenter: Graziela Zibetti Dal Molin
Session: Poster session 11